Secor Capital Advisors’s Anika Therapeutics ANIK Stock Holding History

Secor Capital Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-20,574	Closed	-$691K	–	404
2018 Q4	$691K	Buy	+20,574	New	+$743K	0.09%	268
2017 Q1	–	Sell	-46,984	Closed	-$2.3M	–	455
2016 Q4	$2.3M	Sell	46,984 -21,460	-31%	-$992K	0.28%	110
2016 Q3	$3.27M	Buy	68,444 +39,884	+140%	+$1.97M	0.36%	80
2016 Q2	$1.53M	Buy	28,560 +14,286	+100%	+$673K	0.19%	163
2016 Q1	$638K	Sell	14,274 -8,534	-37%	-$346K	0.09%	268
2015 Q4	$870K	Buy	+22,808	New	+$872K	0.25%	136
2015 Q3	–	Sell	-18,065	Closed	-$597K	–	493
2015 Q2	$597K	Buy	+18,065	New	+$644K	0.21%	172
2014 Q1	–	Sell	-15,871	Closed	-$606K	–	277
2013 Q4	$606K	Buy	+15,871	New	+$490K	0.24%	175

Other funds holding ANIK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Secor Capital Advisors's ANIK Position: Q1 2019 in Review

Secor Capital Advisors sold out of Anika Therapeutics (ANIK) in Q1 2019, closing a stake of 20,574 shares — an estimated $691K sold.

Secor Capital Advisors first reported a position in ANIK in Q4 2013 and held it in 8 quarters. The position peaked at $3.27M in Q3 2016. 157 funds tracked by Wall St. Rank hold ANIK as of Q1 2019.

Secor Capital Advisors reported no remaining Anika Therapeutics position as of Q1 2019 after selling out during the quarter.
Secor Capital Advisors sold 20,574 Anika Therapeutics shares in Q1 2019, an estimated $691K.
Secor Capital Advisors first reported a position in Anika Therapeutics in Q4 2013 and held it in 8 quarters.
Secor Capital Advisors's Anika Therapeutics position peaked at $3.27M in Q3 2016.
157 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2019.

Based on Secor Capital Advisors's 13F filing for Q1 2019, filed 15 May 2019.